ArticleJournal of orthopaedic surgery and research2026
Long non-coding RNA CKMT2-AS1 serves as a biomarker for osteoarthritis and participates in chondrocyte injury via miR-6720-5p.
Article in Journal of orthopaedic surgery and research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe function of long non-coding RNAs (lncRNAs) in osteoarthritis is increasingly recognized. CKMT2-AS1 has been reported to be dysregulated in osteoarthritis, but its biological function remains unknown.
objectiveThe objective is to investigate the expression and function of CKMT2-AS1 in osteoarthritis, providing a biomarker and a promising therapeutic target.
methodsExpression of CKMT2-AS1 was determined in human osteoarthritic cartilage and IL-1β-induced chondrocyte models. Gain-of-function experiments were conducted by overexpressing CKMT2-AS1 in CHON-001 cells. Inflammatory cytokines (IL-6, TNF-α) and extracellular matrix (ECM)-related markers (ACAN, COL2A1, MMP3, MMP13) were assessed via ELISA and RT-qPCR, respectively. EdU, CCK-8, and flow cytometry assays were employed to evaluate cell proliferation and apoptosis. The interaction between CKMT2-AS1 and miR-6720-5p was validated by luciferase reporter assay and RIP assay. Bioinformatics tools predicted the targets of miR-6720-5p, which underwent GO and KEGG enrichment analysis.
resultsCKMT2-AS1 was downregulated in osteoarthritic cartilage and IL-1β-induced chondrocytes. Overexpression of CKMT2-AS1 alleviated IL-1β-induced inflammation, ECM degradation, proliferation inhibition, and apoptosis. Mechanistically, CKMT2-AS1 acted as a molecular sponge for miR-6720-5p, which was upregulated in osteoarthritis. The functional role of the CKMT2-AS1/miR-6720-5p axis was validated through rescue experiments. miR-6720-5p overexpression effectively reversed the protective effect of CKMT2-AS1. Additionally, the target genes of miR-6720-5p were enriched in pathways such as "Hippo signaling" and "arginine biosynthesis."
conclusionsThis study reveals the downregulation of CKMT2-AS1 in osteoarthritis and its protective role against chondrocyte injury via miR-6720-5p, highlighting its novel function as a potential therapeutic target for osteoarthritis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.